UPDATED JULY 3: The Food and Drug Administration has approved Kisunla (generic name donanemab), a new Alzheimer’s drug developed by Eli Lilly. The published data…
The Food and Drug Administration has decided to postpone its decision on the approval of Eli Lilly’s candidate Alzheimer’s drug, donanemab. The delay has…
American pharmaceutical company Eli Lilly announced in May 2023 that it had seen encouraging clinical trial results of its new Alzheimer’s medication. According to…
After almost two decades of stagnation, two new drugs for Alzheimer’s have hit the market in the last three years. The approval of Biogen…
According to drugmaker Eli Lilly, the FDA has rejected the company’s application for the FDA’s “Accelerated Approval” designation for experimental Alzheimer’s drug donanemab. The…
In Being Patient’s LiveTalk series, Dr. David Weidman, associate medical director for research at the Banner Alzheimer’s Institute, shares insights on Eli Lilly’s investigational Alzheimer’s…
This weekend, Eli Lilly and Company presented detailed results of its phase 2 TRAILBLAZER-ALZ trial, showing that its investigational drug donanemab — monoclonal antibody…
(UPDATED Sat. March 13, 2021) In January, excitement rippled through the Alzheimer’s community with drugmaker Eli Lilly and Company’s announcement that their experimental drug…
The initial results from Eli Lilly and Co’s Phase 2 clinical trial for experimental Alzheimer’s drug donanemab provide much needed hope for the Alzheimer’s…
When Jamie Tyrone opened the e-mail from a direct-to-consumer DNA company, she thought she was satisfying a casual curiosity. Instead, she learned she carries…
A decade ago, families confronting an Alzheimer’s diagnosis had little more than memory-boosting pills aimed at lessening symptoms but they didn’t halt disease progression….
After being rejected by EU regulators but approved in the U.S., UK, and several Middle Eastern countries, Alzheimer’s drug Kisunla added a new market:…
This installment of our quarterly Trials Update captures the latest developments in Alzheimer’s and other dementia clinical trials, from January 2025 to present. We’ve…
Two scientists at the University of Washington lay out how U.S. cuts to science research funding are expected to have a resounding public health…
The Alzheimer’s Association’s latest “Facts and Figures” report finds most Americans want early screening and access to disease-modifying drugs — even at high cost…